| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
i-Inositol-d6 does not have a specific pharmacological target as it is a stable isotope-labeled tracer. Myo-inositol itself is involved in various cellular processes including signal transduction, osmoregulation, and as a precursor for phosphatidylinositol and inositol phosphates. The deuterated form is used as a tracer to study inositol metabolism and its role in cellular signaling pathways. Its "target" in research is the metabolic pathways involving inositol and its derivatives.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro activity of i-Inositol-d6 is measured as its utility as a tracer in metabolic studies rather than as a bioactive compound. In cell culture, the labeled inositol is incorporated into cellular lipids and signaling molecules, allowing for tracking via mass spectrometry or NMR spectroscopy. Its "activity" is reflected in its metabolic incorporation and its ability to serve as a probe for studying inositol metabolism, phosphoinositide signaling, and cellular osmoregulation in various cell types. |
| ln Vivo |
In vivo, i-Inositol-d6 is used to study inositol metabolism, distribution, and turnover in living organisms. Administered orally or intravenously, the labeled inositol is absorbed, distributed to tissues, and incorporated into phospholipids and other inositol-containing molecules. These studies provide quantitative data on inositol kinetics, tissue distribution, and the role of inositol in various physiological processes. It is particularly valuable for studying metabolic disorders and the role of inositol in insulin signaling and polycystic ovary syndrome.
|
| Enzyme Assay |
In vitro enzyme assays with i-Inositol-d6 typically involve studying enzymes of inositol metabolism such as inositol-3-phosphate synthase, inositol monophosphatase, and inositol kinases. The labeled substrate is incubated with enzyme preparations in appropriate buffers, and the reaction products are analyzed by mass spectrometry to quantify the conversion to inositol phosphates or other metabolites. These assays provide mechanistic insights into enzyme kinetics and the regulation of inositol metabolism.
|
| Cell Assay |
In vitro cell culture experiments with i-Inositol-d6 involve supplementing cell culture media with the labeled inositol. Cells are cultured for various periods to allow incorporation of the label into cellular inositol lipids and signaling molecules. Following incubation, cells are harvested, lipids or metabolites are extracted, and isotopic enrichment is measured by mass spectrometry. These experiments are used to study inositol metabolism, phosphoinositide signaling, and the role of inositol in cellular functions such as proliferation, differentiation, and stress responses.
|
| Animal Protocol |
In vivo animal experiments with i-Inositol-d6 typically involve administering the labeled compound via oral gavage or intravenous injection to rodents. Blood, tissues (liver, brain, kidney), and excreta are collected at various time points. Isotopic enrichment of inositol and its metabolites in plasma and tissues is measured by mass spectrometry. These studies provide quantitative data on whole-body inositol metabolism, including absorption, distribution, incorporation into tissues, and excretion. They are used to investigate the role of inositol in development, metabolism, and disease.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of i-Inositol-d6 are essentially identical to those of natural myo-inositol. Inositol is absorbed from the gastrointestinal tract via sodium-dependent transporters, distributed throughout the body, and incorporated into cellular lipids or metabolized. It is primarily excreted by the kidneys. The deuterium label allows for precise tracking of the compound's distribution and metabolism using mass spectrometry. In research, it is used as a tracer for studying inositol metabolism and as a quantitative tracer in drug development.
|
| Toxicity/Toxicokinetics |
i-Inositol-d6 has a low toxicity profile consistent with natural inositol, which is a normal component of the diet and cellular metabolism. The deuterium label does not introduce additional toxicity. At normal physiological concentrations, inositol is safe and well-tolerated. For research use, standard laboratory safety practices are sufficient. The compound is classified as an endogenous metabolite and a stable isotope.
|
| References | |
| Additional Infomation |
i-Inositol-d6 is a research-grade stable isotope-labeled compound used primarily as a tracer in metabolic and biochemical studies. Its isotopic substitution allows researchers to use NMR spectroscopy and mass spectrometry to track inositol metabolic pathways with high specificity. It is a deuterated form of i-inositol, a compound associated with lipids in many foods. The compound is not a drug and has no clinical trials or therapeutic indications. It is available for laboratory research use only, serving as a critical tool for understanding inositol metabolism and cellular signaling.
|
| Molecular Formula |
C6H6D6O6
|
|---|---|
| Molecular Weight |
186.19
|
| Exact Mass |
186.101
|
| CAS # |
68922-44-1
|
| Related CAS # |
i-Inositol;87-89-8
|
| PubChem CID |
12302985
|
| Appearance |
White to off-white solid powder
|
| LogP |
-3.7
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C1(C(C(C(C(C1([2H])O)([2H])O)([2H])O)([2H])O)([2H])O)O
|
| InChi Key |
CDAISMWEOUEBRE-MZWXYZOWSA-N
|
| InChi Code |
InChI=1S/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/i1D,2D,3D,4D,5D,6D
|
| Chemical Name |
1,2,3,4,5,6-hexadeuteriocyclohexane-1,2,3,4,5,6-hexol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3709 mL | 26.8543 mL | 53.7086 mL | |
| 5 mM | 1.0742 mL | 5.3709 mL | 10.7417 mL | |
| 10 mM | 0.5371 mL | 2.6854 mL | 5.3709 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
